Wave Life Sciences Ltd. SEC Filings

Wave Life Sciences, Inc. underwent a redomiciliation on August 7, 2026, in which Wave Life Sciences, Inc., a Delaware corporation, became the ultimate parent of the Wave Life Sciences group. Under a Scheme of Arrangement, all ordinary shares of Wave Life Sciences Ltd. were exchanged one-for-one for new shares of Wave Life Sciences, Inc. common stock, par value $0.001 per share, and Wave Life Sciences Ltd. became its wholly owned subsidiary.

RA Capital Management, L.P., Peter Kolchinsky, Rajeev Shah, and RA Capital Healthcare Fund, L.P. report beneficial ownership of 34,314,406 shares of Wave Life Sciences common stock, representing 16.8% of the class. This position consists of 26,975,505 shares held by the Fund, 7,093,656 shares issuable upon exercise of Pre-Funded Warrants, and additional shares and options held by Dr. Kolchinsky for the benefit of RA Capital. The reporting persons generally have shared voting and dispositive power and include recent vesting of 76,200 options at an exercise price of $8.11 and 12,700 restricted stock units on August 11, 2026.

Wave Life Sciences, Inc. filed a post-effective amendment to an existing shelf registration to reflect its redomiciliation from Singapore to Delaware and to adopt the prior Form S-3 under Rule 414 as its own. The amendment covers the resale of up to 7,072,781 shares of common stock by existing selling stockholders. These shares were originally issued by Wave’s Singapore predecessor in various private financings, debt exchanges and its 2015 IPO, and were converted one-for-one into Delaware common stock on August 7, 2026. All shares registered are already outstanding, and the company states it will not receive any proceeds from their sale. As of June 30, 2026, there were 193,277,622 shares of common stock outstanding. The stock trades on the Nasdaq Global Market under the symbol WVE, with a last reported price of $5.74 on August 3, 2026. The filing also describes the new Delaware capital structure, anti-takeover provisions, pre-funded warrants, and existing registration rights for major partners.

Wave Life Sciences, Inc. (WVE) has filed a post-effective amendment to its automatic shelf registration on Form S-3 to reflect its redomiciliation from Singapore to Delaware and related corporate changes, without registering any additional securities or paying new fees. All outstanding ordinary shares of the former Singapore parent were exchanged on a one-for-one basis for shares of Wave Life Sciences, Inc. common stock, and the Singapore entity became a subsidiary.

The amended base shelf allows the company, as a well-known seasoned issuer, to issue from time to time common stock, debt securities, warrants, rights and units, with specific terms to be set in future prospectus supplements. A related amended and restated open market sale agreement with Jefferies LLC provides for an at-the-market program of up to $250,000,000 of common stock; after prior sales of $101,381,538, capacity of up to $148,618,462 remains. Common stock is listed on The Nasdaq Global Market under the symbol WVE, with a last reported price of $5.74 on August 3, 2026.

Wave Life Sciences Ltd. reported a net loss of $69,355 thousand for the three months ended June 30, 2026, on collaboration revenue of $2,272 thousand, as operating expenses reached $76,074 thousand driven by $51,293 thousand in research and development and $24,781 thousand in general and administrative costs. For the first six months of 2026, revenue was $40,518 thousand and net loss was $95,442 thousand. Management stated that cash, cash equivalents and marketable securities of $490.6 million as of June 30, 2026 are expected to fund operations for at least twelve months.

The company remains a clinical‑stage RNA medicines developer with lead programs in obesity (WVE‑007), alpha‑1 antitrypsin deficiency (WVE‑006), PNPLA3 I148M liver disease (WVE‑008), Duchenne muscular dystrophy and Huntington’s disease, all built on its PRISM platform. Wave recognized $2,272 thousand of GSK collaboration revenue in the quarter and has about $22.6 million of deferred revenue remaining. It regained full rights to WVE‑006, advanced multiple clinical trials, and plans additional data readouts in 2026. Structural steps include a court‑approved redomiciliation from Singapore to Delaware expected in August 2026 and an extension of its Lexington, Massachusetts manufacturing lease, which increased operating lease right‑of‑use assets and liabilities by approximately $30.0 million.

Wave Life Sciences reported financial results for the quarter ended June 30, 2026. Revenue was $2,272 thousand and the net loss was $69,355 thousand, or $0.34 per basic and diluted share, as research and development plus general and administrative expenses totaled $76,074 thousand. For the first half of 2026, revenue reached $40,518 thousand with a net loss of $95,442 thousand.

The company highlighted progress across its RNA medicines pipeline. Dosing is underway in the Phase 2a multidose INLIGHT trial of obesity candidate WVE-007, and Phase 2 combination and post-incretin maintenance trials are described as on track to initiate in the second half of 2026. In alpha-1 antitrypsin deficiency, an FDA meeting is scheduled for the end of summer 2026 to discuss a potential accelerated approval pathway for RNA editing candidate WVE-006. A clinical trial application submission for liver disease program WVE-008 is described as on track for the second half of 2026. Management characterizes the company as well capitalized, citing $490.6 million in cash, cash equivalents and marketable securities as of June 30, 2026, with an expected cash runway into the third quarter of 2028.

Wave Life Sciences Ltd. reported that its shareholders approved a court-supervised Scheme of Arrangement needed to complete the company’s redomiciliation. At a special meeting on June 22, 2026, 87 Scheme Shareholders voted, with all 87 voting in favor and none against.

These holders cast 155,190,836 shares for the Wave Redomiciliation Proposal and 78,429 shares against, for a total of 155,269,265 shares voted. The company will now apply to the Singapore High Court for approval of the Scheme of Arrangement and, if granted, expects the redomiciliation to take effect in mid‑2026.

Wave Life Sciences reported a positive update from its RestorAATion-2 Phase 1b/2a trial of WVE-006 for alpha-1 antitrypsin deficiency. WVE-006, a subcutaneous RNA editing therapy, reduced harmful Z-AAT protein and restored protective M-AAT to levels resembling low-risk MZ individuals with both biweekly and monthly dosing.

In the 200 mg biweekly cohort, total AAT reached 11.9 µM and M-AAT rose to 64.4% of total, while Z-AAT fell by 71%. A 400 mg monthly regimen produced similar effects, with 13.6 µM total AAT and strong Z-AAT reductions. Three acute infections triggered rapid AAT surges, showing restored dynamic protein production.

Editing effects were sustained for at least three months after the last dose, and WVE-006 was generally well tolerated with only mild to moderate adverse events and no serious events or liver test issues. Wave expects mid-2026 FDA feedback on a potential accelerated approval pathway and is hosting an investor webcast to discuss the data.